Search Medical Condition
Please enter condition
Please choose location from dropdown

Higashi-ku,Fukuoka, Japan Clinical Trials

A listing of Higashi-ku,Fukuoka, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (192) clinical trials

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses

This is a multi-center, randomized, phase 2 trial to characterize the safety and efficacy of ponatinib over a range of 3 starting doses. Eligible participants must have chronic phase chronic myeloid leukemia (CP-CML) and have demonstrated resistance to treatment or have the T315I mutation.

Phase

0.44 miles

Learn More »

An Investigational Immuno-therapy Trial of Nivolumab or Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum-doublet Chemotherapy Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.

Phase

0.44 miles

Learn More »

Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety

This is a Phase IV, randomized, open-label, active-controlled, 2-arm, multicenter study. The primary objective will be assessed by the difference in the mean number of ranibizumab injections applied up to Month 11 between the 2 treatment arms. Patients will be randomized in a 1:1 ratio to 1 of the 2 ...

Phase

0.7 miles

Learn More »

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Well-differentiated Non-functional Neuroendocrine Tumors of Pancreatic Gastrointestinal (GI) or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

This is a study to investigate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) that have progressed on prior treatment.

Phase

0.7 miles

Learn More »

A Study of the Anti-PD1 Antibody PDR001 in Combination With Dabrafenib and Trametinib in Advanced Melanoma

To evaluate the safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma

Phase

0.7 miles

Learn More »

Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support

The purpose of this study is to determine if an investigational treatment (teduglutide) is safe and effective in Japanese children (age 1 through 15 years of age) with SBS who are dependent on parenteral support. This study will also evaluate how teduglutide moves through the body (pharmacokinetics) and how it ...

Phase

0.7 miles

Learn More »

Study of Olaparib (Lynparza ) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

This is a prospective, multicenter, randomized, open-label, phase 3 trial evaluating the efficacy and safety of olaparib versus enzalutamide or abiraterone in subjects with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior treatment with a new hormonal agent (NHA) and have a qualifying tumor mutation in one of 15 ...

Phase

0.7 miles

Learn More »

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of Ineligibility For or Refusal of a Taxane Regimen

This Phase III, multicenter, randomized, open-label study will evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) in combination with enzalutamide compared with enzalutamide alone in participants with mCRPC after failure of an androgen synthesis inhibitor (e.g., abiraterone) and failure of, ineligibility for, or refusal of a ...

Phase

0.7 miles

Learn More »

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy

This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy.

Phase

0.7 miles

Learn More »

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.

Phase

0.7 miles

Learn More »